Aristotle Capital Boston LLC Cuts Stock Holdings in Chemed Corporation $CHE

Aristotle Capital Boston LLC lessened its holdings in Chemed Corporation (NYSE:CHE) by 5.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 60,643 shares of the company’s stock after selling 3,449 shares during the quarter. Chemed makes up about 1.4% of Aristotle Capital Boston LLC’s holdings, making the stock its 13th largest position. Aristotle Capital Boston LLC’s holdings in Chemed were worth $25,947,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Los Angeles Capital Management LLC acquired a new stake in shares of Chemed during the fourth quarter worth about $26,000. Smartleaf Asset Management LLC grew its holdings in shares of Chemed by 71.4% during the third quarter. Smartleaf Asset Management LLC now owns 60 shares of the company’s stock worth $27,000 after buying an additional 25 shares during the last quarter. BOK Financial Private Wealth Inc. acquired a new stake in Chemed in the fourth quarter valued at about $27,000. Global Retirement Partners LLC lifted its position in Chemed by 200.0% in the fourth quarter. Global Retirement Partners LLC now owns 87 shares of the company’s stock valued at $37,000 after purchasing an additional 58 shares during the period. Finally, Geneos Wealth Management Inc. lifted its position in Chemed by 330.4% in the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after purchasing an additional 76 shares during the period. Institutional investors and hedge funds own 95.85% of the company’s stock.

Chemed Price Performance

CHE stock opened at $435.74 on Thursday. The firm has a 50 day moving average of $418.15 and a 200-day moving average of $424.20. Chemed Corporation has a 12-month low of $365.20 and a 12-month high of $562.77. The company has a current ratio of 0.85, a quick ratio of 0.83 and a debt-to-equity ratio of 0.11. The company has a market cap of $5.78 billion, a price-to-earnings ratio of 23.75, a PEG ratio of 1.63 and a beta of 0.54.

Chemed (NYSE:CHE) last posted its quarterly earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.30 by $0.35. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The company had revenue of $657.51 million during the quarter, compared to the consensus estimate of $659.22 million. During the same period last year, the firm earned $5.63 EPS. The company’s revenue for the quarter was up 1.6% on a year-over-year basis. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. As a group, equities analysts expect that Chemed Corporation will post 22.3 EPS for the current fiscal year.

Chemed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Thursday, May 28th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Thursday, May 28th. Chemed’s dividend payout ratio (DPR) is presently 13.08%.

Insider Buying and Selling

In related news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $421.13, for a total transaction of $842,260.00. Following the completion of the transaction, the chief executive officer directly owned 90,219 shares in the company, valued at $37,993,927.47. The trade was a 2.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Andrea R. Lindell sold 1,347 shares of Chemed stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $447.33, for a total value of $602,553.51. Following the transaction, the director owned 4,578 shares of the company’s stock, valued at $2,047,876.74. This represents a 22.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.33% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

CHE has been the subject of a number of recent analyst reports. Royal Bank Of Canada raised their price objective on shares of Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a research report on Monday, April 27th. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Wall Street Zen downgraded shares of Chemed from a “buy” rating to a “hold” rating in a research report on Monday, June 8th. Oppenheimer reduced their price objective on shares of Chemed from $580.00 to $500.00 and set an “outperform” rating for the company in a research report on Friday, February 27th. Finally, Weiss Ratings upgraded shares of Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Chemed currently has a consensus rating of “Hold” and an average price target of $501.50.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.